Corporate ActionMay 1, 2026, 04:08 PM
Lakewood-Amedex Registers 9.65M Shares for Resale; Funds Phase 2a Trial
AI Summary
Lakewood-Amedex Biotherapeutics Inc. filed an S-1 registration statement for the resale of 9,647,726 shares of common stock by selling stockholders. This includes 9,375,000 shares convertible from Series C Preferred Stock issued in a January 2026 private placement and 272,726 shares issued for advisory services. The proceeds from the Series C financing are earmarked to fund the upcoming Phase 2a clinical trial for its lead product, Nu-3 gel, targeting mildly infected diabetic foot ulcers. The company, an emerging growth and smaller reporting company, has its common stock trading on Nasdaq under "LABT".
Key Highlights
- Registers 9,647,726 common shares for resale by selling stockholders.
- Includes 9,375,000 shares from Series C Preferred Stock private placement.
- Series C Preferred Stock sold at $10.00/share (20% discount), convertible at $1.00 floor.
- Issued 272,726 shares to RBW Capital Partners LLC for advisory services.
- Repaid $198,158 in unsecured promissory notes issued in early 2026.
- Proceeds from Series C financing to fund Nu-3 gel Phase 2a clinical trial.
- Nu-3 gel Phase 2a study to use 2%, 5%, and 10% gels, twice daily.
- Common stock trades on Nasdaq under "LABT"; last sale price $2.66 on May 30, 2026.
Price Impact
More from LABT